Clarity Pharmaceuticals Ltd
ASX:CU6
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.46
5.7
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one CU6 stock under the Base Case scenario is 0.5 AUD. Compared to the current market price of 3.36 AUD, Clarity Pharmaceuticals Ltd is Overvalued by 85%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Clarity Pharmaceuticals Ltd.
| US |
|
Eli Lilly and Co
NYSE:LLY
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Clarity's success hinges on its unproven copper-based radiopharmaceuticals; any unexpected safety issues or lack of efficacy data from ongoing clinical trials could significantly undermine investor confidence and jeopardize future funding.
The company’s focus on highly specialized radiopharmaceuticals exposes it to elevated supply chain risks, particularly in securing isotope production and handling. Even minor disruptions can delay R&D timelines and erode Clarity’s competitive advantage.
Heightened competition from established radiotherapy players with larger R&D budgets and deeper commercialization experience may overshadow Clarity’s marketing efforts, slowing adoption and limiting its share in the growing nuclear medicine market.
Clarity’s copper-based radiopharmaceutical platform offers a differentiated approach with the potential for improved diagnostic accuracy and therapeutic effectiveness, putting it at the forefront of next-generation radiotherapy innovation.
The company’s expanding oncology pipeline, targeting multiple cancer indications with precisely targeted nuclear therapies, could open up significant revenue opportunities if pivotal trial results prove robust and lead to regulatory approvals.
Strategic collaborations with leading academic institutes and hospitals help accelerate Clarity’s clinical development process and strengthen its credibility, potentially translating into faster market adoption and enhanced brand recognition.
Revenue & Expenses Breakdown
Clarity Pharmaceuticals Ltd
Balance Sheet Decomposition
Clarity Pharmaceuticals Ltd
| Current Assets | 100.6m |
| Cash & Short-Term Investments | 84.1m |
| Receivables | 10.1m |
| Other Current Assets | 6.4m |
| Non-Current Assets | 566k |
| PP&E | 552.5k |
| Other Non-Current Assets | 13.5k |
| Current Liabilities | 10.4m |
| Accounts Payable | 3.2m |
| Accrued Liabilities | 2.5m |
| Other Current Liabilities | 4.7m |
| Non-Current Liabilities | 561.8k |
| Other Non-Current Liabilities | 561.8k |
Free Cash Flow Analysis
Clarity Pharmaceuticals Ltd
| AUD | |
| Free Cash Flow | AUD |
Earnings Waterfall
Clarity Pharmaceuticals Ltd
|
Revenue
|
0
AUD
|
|
Operating Expenses
|
-69.1m
AUD
|
|
Operating Income
|
-69.1m
AUD
|
|
Other Expenses
|
4.8m
AUD
|
|
Net Income
|
-64.3m
AUD
|
CU6 Profitability Score
Profitability Due Diligence
Clarity Pharmaceuticals Ltd's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Clarity Pharmaceuticals Ltd's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
CU6 Solvency Score
Solvency Due Diligence
Clarity Pharmaceuticals Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Clarity Pharmaceuticals Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CU6 Price Targets Summary
Clarity Pharmaceuticals Ltd
According to Wall Street analysts, the average 1-year price target for CU6 is 7.55 AUD with a low forecast of 5.05 AUD and a high forecast of 9.66 AUD.
Dividends
Current shareholder yield for CU6 is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one CU6 stock under the Base Case scenario is 0.5 AUD.
Compared to the current market price of 3.36 AUD, Clarity Pharmaceuticals Ltd is Overvalued by 85%.